A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant
Joanne M. Langley(Dalhousie University), Ilse Dieussaert, Maarten Leyssen, Walthère Dewé, Scott A. Halperin(Dalhousie University), Laurence Fissette, Jean‐François Toussaint(Université Paris Cité), Shelly McNeil(Dalhousie University), Azhar Toma(Manna Research), Naresh Aggarwal
Cited by 67
Related Papers
Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments
|Journal of Virological Methods|2006|342
The changing and dynamic epidemiology of meningococcal disease
|Vaccine|2011|304
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
|The Lancet Diabetes & Endocrinology|2017|295
Bluetongue in northern Europe
|Veterinary Record|2006|157